Influence of fingolimod on circulating microRNA levels in multiple sclerosis patients

Next Previous
Trial Profile

Influence of fingolimod on circulating microRNA levels in multiple sclerosis patients

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2014

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic

    • Most Recent Events

    • 06 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top